Amanote Research
Register
Sign In
Effects of a Loading Dose Regimen of Three Infusions of Chimeric Monoclonal Antibody to Tumour Necrosis Factor Alpha (Infliximab) in Spondyloarthropathy: An Open Pilot Study
Annals of the Rheumatic Diseases
- United Kingdom
doi 10.1136/ard.59.6.428
Full Text
Open PDF
Abstract
Available in
full text
Categories
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Date
June 1, 2000
Authors
F. Van den Bosch
Publisher
BMJ
Related search
Treatment of Intestinal Behcet's Syndrome With Chimeric Tumour Necrosis Factor Alpha Antibody
Gut
Gastroenterology
Increase in Bone Mineral Density of Patients With Spondyloarthropathy Treated With Anti-Tumour Necrosis Factor Alpha
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Editorial: CT-P13, a Biosimilar of Anti-Tumour Necrosis Factor-Alpha Agent (Infliximab), in Inflammatory Bowel Diseases
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Infliximab (Anti–Tumor Necrosis Factor Α Antibody)
Archives of Dermatology
Circulating Tumour Necrosis Factor Alpha and Soluble Tumour Necrosis Factor Receptors in Patients With Different Patterns of Rheumatoid Synovitis
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Immunohistochemical Studies of Intrahepatic Tumour Necrosis Factor Alpha in Chronic Liver Disease.
Journal of Clinical Pathology
Medicine
Forensic Medicine
Pathology
Increased Plasma Tumour Necrosis Factor-Alpha Concentration in Atopic Dermatitis.
Archives of Disease in Childhood
Child Health
Pediatrics
Perinatology
Pulmonary Granulomas After Tumour Necrosis Factor Alpha Antagonist Therapy
Thorax
Pulmonary
Respiratory Medicine
Effect of Tumour Necrosis Factor on the Uptake of Specific and Control Monoclonal Antibodies in a Human Tumour Xenograft Model
British Journal of Cancer
Cancer Research
Oncology
